• Capricor Therapeutics appointed Michael Maurer as chief commercial officer, effective immediately, to strengthen launch readiness for Deramiocel in Duchenne muscular dystrophy.
• Maurer brings about two decades in rare-disease commercialization, patient access, and launch strategy, including work at Amicus Therapeutics, Sarepta Therapeutics, and Bristol Myers Squibb.
• At Sarepta, he led the U.S. launch of ELEVIDYS for Duchenne muscular dystrophy, shaping commercial strategy for the company’s approved RNA therapies.
• He will run the global commercial organization, covering market access, patient support, distribution strategy, and operational planning ahead of an Aug. 22, 2026 PDUFA date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.